Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
J Ethnopharmacol ; 324: 117781, 2024 Apr 24.
Article in English | MEDLINE | ID: mdl-38253278

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: The application of Cortex Mori (CM) in the treatment of diabetes mellitus (DM) has been extensively documented in traditional medicine. In recent years, the chemical composition of CM has been gradually unraveled, and its therapeutic mechanism in treating DM, diabetic nephropathy, diabetic cardiomyopathy, and other related conditions has been highlighted in successive reports. However, there is no systematic study on the treatment of DM based on the chemical composition of CM. AIM OF THE STUDY: This study was conducted to systematically explore the hypoglycemic activity mechanism of CM based on its chemical composition. METHODS: The material basis of Cortex Mori extract (CME) was investigated through qualitative analyses based on liquid chromatography-mass spectrometry (LC-MS). The possible acting mechanism was simulated using network pharmacology and validated in streptozotocin (STZ) + high fat diet (HFD)-induced diabetic rats and glucosamine-induced IR-HepG2 model with the assistance of molecular docking techniques. RESULTS: A total of 39 compounds were identified in CME by the LC-MS-based qualitative analysis. In diabetic rats, it was demonstrated that CME significantly ameliorated insulin resistance, blood lipid levels, and liver injury. The network pharmacology analysis predicted five major targets, including AKT1, PI3K, FoxO1, Gsk-3ß, and PPARγ. Additionally, three key compounds (resveratrol, protocatechuic acid, and kaempferol) were selected based on their predicted contributions. The experimental results revealed that CME, resveratrol, protocatechuic acid, and kaempferol could promote the expression of AKT1, PI3K, and PPARγ, while inhibiting the expression of FoxO1 and Gsk-3ß. The molecular docking results indicated a strong binding affinity between resveratrol/kaempferol and their respective targets. CONCLUSIONS: CME contains a substantial amount of prenylated flavonoids, which may be the focal point of research on the efficacy of CM in the treatment of DM. Besides, CME is effective in controlling blood glucose and insulin resistance, improving lipid levels, and mitigating liver injury in patients with DM. Relevant mechanisms may be associated with the activation of the PI3K/Akt pathway, the inhibition of the expression of FoxO1 and Gsk-3ß, and the enhancement of PPARγ activity. This study represents the first report on the role of CME in the treatment of DM through regulating PPARγ, FoxO1, and Gsk-3ß.


Subject(s)
Diabetes Mellitus, Experimental , Drugs, Chinese Herbal , Hydroxybenzoates , Insulin Resistance , Rats , Humans , Animals , Glycogen Synthase Kinase 3 beta , Kaempferols/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Molecular Docking Simulation , Resveratrol , Phosphatidylinositol 3-Kinases/metabolism , PPAR gamma , Lipids/therapeutic use , Proto-Oncogene Proteins c-akt/metabolism , Drugs, Chinese Herbal/pharmacology
2.
Front Pharmacol ; 13: 998965, 2022.
Article in English | MEDLINE | ID: mdl-36330088

ABSTRACT

There are about 20 species of Porana Burm. f. worldwide in tropical and subtropical Asia, Africa and neighboring islands, Oceania, and the Americas. In China, India, and other places, this genus enjoys a wealth of experience in folk applications. Nevertheless, the chemical composition of only five species has been reported, and 59 compounds have been isolated and identified, including steroids, coumarins, flavonoids, quinic acid derivatives, and amides. Pharmacological studies revealed that extracts from this genus and their bioactive components exhibit anti-inflammatory, analgesic, antioxidant, anti-gout, anti-cancer, and anti-diabetic effects. Although this genus is abundant, the development of its pharmacological applications remains limited. This review will systematically summarize the traditional and current uses, chemical compositions, and pharmacological activities of various Porana species. Network analysis was introduced to compare and confirm its output with current research progress to explore the potential targets and pathways of chemical components in this genus. We hope to increase understanding of this genus's medicinal value and suggest directions for rational medicinal development.

3.
J AOAC Int ; 106(1): 179-191, 2022 Dec 22.
Article in English | MEDLINE | ID: mdl-35904536

ABSTRACT

BACKGROUND: Pimpinella thellungiana H. Wolff (P. thellungiana) is widely used as a Chinese medicinal herb to treat coronary heart disease (CHD). However, the bioactive compounds of this herbal medicine have not been defined, and quality control is imperfect. OBJECTIVE: To develop methods for qualitative analysis and improved quality evaluation of P. thellungiana. METHOD: In this study, UHPLC-Q-Exactive Orbitrap MS, network pharmacology, and molecular docking approaches were applied to explore the quality markers of P. thellungiana. A quantitative analysis of multi-components via a single marker (QAMS) method was developed to simultaneously detect nine quality markers of P. thellungiana. RESULTS: Nine compounds were selected as quality markers for quality control of P. thellungiana: protocatechuic acid, neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, luteolin-7-O-glucuronide, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, apigenin-7-O-glucuronide, and 4,5-dicaffeoylquinic acid. The established QAMS method was validated and applied in 10 batches of P. thellungiana samples. CONCLUSIONS: These findings facilitate effective quality evaluation of P. thellungiana and suggest this approach could be applied to evaluate the quality of other herbal medicines. HIGHLIGHTS: UHPLC-Q-Exactive Orbitrap MS was used to detect 36 compounds in P. thellungiana and 40 compounds in rat plasma after dosing with P. thellungiana. Quality markers were selected based on detection of compounds absorbed into rat plasma and network pharmacology analysis.


Subject(s)
Drugs, Chinese Herbal , Pimpinella , Plants, Medicinal , Rats , Animals , Pimpinella/chemistry , Drugs, Chinese Herbal/analysis , Molecular Docking Simulation , Network Pharmacology , Plants, Medicinal/chemistry , Chromatography, High Pressure Liquid/methods
4.
PLoS One ; 17(3): e0264786, 2022.
Article in English | MEDLINE | ID: mdl-35235611

ABSTRACT

BACKGROUND: Porana sinensis Hemsl. has been widely used as a substitute for Erycibes Caulis to treat rheumatoid arthritis (RA) in traditional Chinese medicine (TCM). However, little is known about the active ingredients and pharmacological mechanisms that mediate the action of P. sinensis against RA. METHODS: The compounds contained in P. sinensis were analyzed by Q Exactive Focus mass spectrometer. The active constituents and pharmacological mechanism of P. sinensis against RA were clarified using a network pharmacology-based investigation. LPS-induced RAW 264.7 cells was used to verify anti-inflammatory effects of the active compounds screened by network pharmacology. Collagen-induced arthritis model was used to further investigate the mechanism of P. sinensis against RA. RESULTS: The potential components and targets of P. sinensis against RA were analyzed using network pharmacology, and five compounds, twenty-five targets, and eight pathways were identified. Experimental validation suggested that P. sinensis extract and five compounds (esculetin, umbelliferone, trans-N-feruloyltyramine, caffeic acid and scopolin) could inhibit the release of inflammatory mediators (NO, TNF-α, IL-1ß and IL-6) in LPS-induced RAW 264.7 cell. P. sinensis extract attenuated the severity, pathological changes, and release of cytokines (IL-6 and HIF-1α) during RA progression by regulating the PI3K/AKT and HIF-1 pathways. CONCLUSION: The study provides a basis for the application of P. sinensis against RA. Our findings may provide suggestions for developing P. sinensis into a substitute for Erycibes Caulis.


Subject(s)
Arthritis, Experimental , Arthritis, Rheumatoid , Drugs, Chinese Herbal , Animals , Arthritis, Experimental/drug therapy , Arthritis, Rheumatoid/metabolism , Drugs, Chinese Herbal/adverse effects , Interleukin-6/therapeutic use , Lipopolysaccharides/adverse effects , Network Pharmacology , Phosphatidylinositol 3-Kinases
5.
Biomed Chromatogr ; 34(2): e4726, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31654585

ABSTRACT

Multicompound determination for the quality control of traditional Chinese medicine (TCM) may often be inadequate, since these compounds may not be associated with, or fully represent, the clinical effects of TCM. Moreover, the individual contributions of each constituent to the pharmacological effect are often not considered. In China, Porana sinensis is widely used as a substitute for Erycibe sources to treat joint pain and rheumatoid arthritis. The existing quality control methods for P. sinensis neither consider the individual contributions of various compounds nor control the actual quality associated with different clinical efficacies. In the present study, a novel efficacy-oriented approach, named the effect-constituent index (ECI), was established for P. sinensis. Analyses of the spectrum-effect relationship and components in rat plasma were conducted to systematically and scientifically select quality markers. Quantitative analysis of multicomponents via a single marker method was introduced to enhance the practical application value of the established ECI. The established ECI shows a good ability to distinguish and predict the bioeffect-based quality of P. sinensis. The present study also provides a reference for the establishment and application of ECI as a quality control method for TCMs.


Subject(s)
Convolvulaceae/chemistry , Drugs, Chinese Herbal , Animals , Chlorogenic Acid/blood , Chlorogenic Acid/chemistry , Chlorogenic Acid/pharmacokinetics , Chromatography, High Pressure Liquid , Coumarins/blood , Coumarins/chemistry , Coumarins/pharmacokinetics , Drugs, Chinese Herbal/analysis , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/metabolism , Drugs, Chinese Herbal/standards , Glucosides/blood , Glucosides/chemistry , Glucosides/pharmacokinetics , Linear Models , Medicine, Chinese Traditional , Quality Control , Quinic Acid/analogs & derivatives , Quinic Acid/blood , Quinic Acid/chemistry , Quinic Acid/pharmacokinetics , Rats , Rats, Sprague-Dawley , Reproducibility of Results
6.
Biomed Chromatogr ; 32(11): e4328, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29975423

ABSTRACT

Morus alba L has long been used as fodder and as a traditional medicine. The different parts of M. alba (Cortex Mori, Ramulus Mori, Folium Mori and Fructus Mori) have different bioactivities; however, most current evidence is focused on anti-diabetic properties. In spite of their widespread use, few studies have compared the chemical composition and activity against α-glucosidase of the various medicinal parts of M. alba. In this study, we developed an HPLC method for simultaneous quality control and discrimination of Cortex Mori, Ramulus Mori, Folium Mori and Fructus Mori using 13 marker compounds. We found that quercetin, morin, kuwanon G, sanggenon C, morusin, mulberroside A and rutin were chemically distinct among the various medicinal parts of M. alba. A spectrum-effect relationship method was established to compare α-glucosidase inhibitory activity of various batches of samples to determine the activity of the primary active components against α-glucosidase. Taken together with molecular docking data, we found that prenylated flavonoids (morin, sanggenon C, kuwanon G and morusin), flavonols (kaempferol, quercetin, rutin and isoquercitrin) and alkaloids (1-deoxynojirimycin) were small molecule α-glucosidase inhibitory ingredients. In conclusion, we laid a solid foundation for effective substance identification in various parts of M. alba, and simultaneously provided a basis for their quality control.


Subject(s)
Glycoside Hydrolase Inhibitors/chemistry , Morus/chemistry , Plant Extracts/chemistry , Alkaloids/analysis , Alkaloids/chemistry , Chromatography, High Pressure Liquid , Flavonoids/analysis , Flavonoids/chemistry , Glycoside Hydrolase Inhibitors/analysis , Molecular Docking Simulation , Plant Extracts/analysis , Principal Component Analysis
SELECTION OF CITATIONS
SEARCH DETAIL